Trials / Completed
CompletedNCT06795698
The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients.
The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients. a Phase 2, Randomized, Doble Blind, Control Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Hospital Civil de Guadalajara · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
the risk of bleeding may be greater than the benefit of antithrombotic protection when prophylactically anticoagulating a patient with a lower limb fracture and advanced CKD. The primary objective was to evaluate the risk major bleeding in patients with lower limb fractures and advance CKD. The secondary objectives were to assess major bleeding in patients with lower limb fractures in CKD stage 4 and 5, thrombosis, death.
Conditions
- Fractures, Bone
- CKD Stage 4
- CKD Stage 3
- CKD Stage 5
- Enoxaparin Adverse Reaction
- Anticoagulant-induced Bleeding
- Thromboses, Venous
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enoxaparin | enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2 |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2025-01-28
- Last updated
- 2025-01-28
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT06795698. Inclusion in this directory is not an endorsement.